Constructing a prognostic risk model for Alzheimer’s disease based on ferroptosis

Introduction The aim of this study is to establish a prognostic risk model based on ferroptosis to prognosticate the severity of Alzheimer’s disease (AD) through gene expression changes. Methods The GSE138260 dataset was initially downloaded from the Gene expression Omnibus database. The ssGSEA algorithm was used to evaluate the immune infiltration of 28 kinds of immune cells in 36 samples. The up-regulated immune cells were divided into Cluster 1 group and Cluster 2 group, and the differences were analyzed. The LASSO regression analysis was used to establish the optimal scoring model. Cell Counting Kit-8 and Real Time Quantitative PCR were used to verify the effect of different concentrations of Aβ1–42 on the expression profile of representative genes in vitro. Results Based on the differential expression analysis, there were 14 up-regulated genes and 18 down-regulated genes between the control group and Cluster 1 group. Cluster 1 and Cluster 2 groups were differentially analyzed, and 50 up-regulated genes and 101 down-regulated genes were obtained. Finally, nine common differential genes were selected to establish the optimal scoring model. In vitro, CCK-8 experiments showed that the survival rate of cells decreased significantly with the increase of Aβ1–42 concentration compared with the control group. Moreover, RT-qPCR showed that with the increase of Aβ1–42 concentration, the expression of POR decreased first and then increased; RUFY3 was firstly increased and then decreased. Discussion The establishment of this research model can help clinicians make decisions on the severity of AD, thus providing better guidance for the clinical treatment of Alzheimer’s disease.

[1]  Bo Han,et al.  Bioinformatic analysis of underlying mechanisms of Kawasaki disease via Weighted Gene Correlation Network Analysis (WGCNA) and the Least Absolute Shrinkage and Selection Operator method (LASSO) regression model , 2023, BMC Pediatrics.

[2]  Qi Wang,et al.  Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma , 2022, Frontiers in Immunology.

[3]  Ixavier A. Higgins,et al.  Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease , 2022, Alzheimer's Research & Therapy.

[4]  Kun Zhao,et al.  Integrated analysis and identification of hub genes as novel biomarkers for Alzheimer’s disease , 2022, Frontiers in Aging Neuroscience.

[5]  Y. Chu,et al.  The mechanisms of ferroptosis and its role in alzheimer’s disease , 2022, Frontiers in Molecular Biosciences.

[6]  R. Priefer,et al.  Alzheimer's disease failed clinical trials. , 2022, Life sciences.

[7]  Y. Li,et al.  Applying logistic LASSO regression for the diagnosis of atypical Crohn's disease , 2022, Scientific Reports.

[8]  J. Yu,et al.  Emerging Mechanisms and Targeted Therapy of Ferroptosis in Neurological Diseases and Neuro-oncology , 2022, International journal of biological sciences.

[9]  O. Hansson,et al.  Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials , 2022, The Lancet Neurology.

[10]  A. Bush,et al.  Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations , 2022, Cell Death & Differentiation.

[11]  Xiaowen Chen,et al.  Diagnostic accuracy study of automated stratification of Alzheimer’s disease and mild cognitive impairment via deep learning based on MRI , 2022, Annals of translational medicine.

[12]  A. Bush,et al.  Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease , 2021, Journal of neurochemistry.

[13]  Qing-Fei Zhao,et al.  A simple nomogram prediction model to identify relatively young patients with mild cognitive impairment who may progress to Alzheimer’s disease , 2021, Journal of Clinical Neuroscience.

[14]  Ling-Qiang Zhu,et al.  Ferroptosis, a Potential Therapeutic Target in Alzheimer’s Disease , 2021, Frontiers in Cell and Developmental Biology.

[15]  Hao Li,et al.  Integrated Analysis of Weighted Gene Coexpression Network Analysis Identifying Six Genes as Novel Biomarkers for Alzheimer's Disease , 2021, Oxidative medicine and cellular longevity.

[16]  A. Luo,et al.  Retrospective Study on the Influencing Factors and Prediction of Hospitalization Expenses for Chronic Renal Failure in China Based on Random Forest and LASSO Regression , 2021, Frontiers in Public Health.

[17]  G. Stokin,et al.  Neuroinflammation in Alzheimer’s Disease , 2021, Biomedicines.

[18]  Chadwick M. Hales,et al.  Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase and ethanolamides metabolism with Alzheimer's disease , 2021, medRxiv.

[19]  Nian Chen,et al.  Identification of Potential Early Diagnostic Biomarkers of Sepsis , 2021, Journal of inflammation research.

[20]  A. Belaidi,et al.  Ferroptosis: mechanisms and links with diseases , 2021, Signal Transduction and Targeted Therapy.

[21]  P. Nelson,et al.  Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease , 2021, Cell Death & Differentiation.

[22]  Kunzheng Wang,et al.  A nine-hub-gene signature of metabolic syndrome identified using machine learning algorithms and integrated bioinformatics , 2021, Bioengineered.

[23]  Dewang Mao,et al.  Prediction of the progression from mild cognitive impairment to Alzheimer’s disease using a radiomics-integrated model , 2021, Therapeutic advances in neurological disorders.

[24]  P. Stadler,et al.  Alzheimer-related genes show accelerated evolution , 2020, Molecular Psychiatry.

[25]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[26]  P. Pan,et al.  Theory of mind in Alzheimer’s disease and amnestic mild cognitive impairment: a meta-analysis , 2020, Neurological Sciences.

[27]  L. Buée,et al.  NLRP3 inflammasome activation drives tau pathology , 2019, Nature.

[28]  S. Acton,et al.  An Efficient Convolutional Neural Network for Coronary Heart Disease Prediction , 2019, Expert Syst. Appl..

[29]  Yingyan Yu,et al.  A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis , 2019, Journal of Experimental & Clinical Cancer Research.

[30]  A. Bush,et al.  Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease , 2019, Pharmaceuticals.

[31]  Nicola Thrupp,et al.  The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques , 2019, Cell reports.

[32]  A. Bush,et al.  Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology , 2019, Neurobiology of Disease.

[33]  A. Bush,et al.  Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration , 2019, Free radical biology & medicine.

[34]  Sara C. Madeira,et al.  Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer’s disease: a feature selection ensemble combining stability and predictability , 2018, BMC Medical Informatics and Decision Making.

[35]  P. Rosa-Neto,et al.  Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[36]  Jelle J. Goeman,et al.  Postmortem T2*- Weighted MRI Imaging of Cortical Iron Reflects Severity of Alzheimer’s Disease , 2018, Journal of Alzheimer's disease : JAD.

[37]  Stavros I. Dimitriadis,et al.  How random is the random forest? Random forest algorithm on the service of structural imaging biomarkers for Alzheimer's disease: from Alzheimer's disease neuroimaging initiative (ADNI) database , 2018, Neural regeneration research.

[38]  Kan Li,et al.  A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time-to-event data , 2018, Alzheimer's & Dementia.

[39]  D. Perani,et al.  FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort , 2018, NeuroImage: Clinical.

[40]  Marjolein Bulk,et al.  Cortical Iron Reflects Severity of Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[41]  P. Payoux,et al.  Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database , 2017, Alzheimer's Research & Therapy.

[42]  K. Blennow,et al.  Alzheimer's disease , 2016, The Lancet.

[43]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[44]  Jean-Francois Mangin,et al.  R2* mapping for brain iron: associations with cognition in normal aging , 2015, Neurobiology of Aging.

[45]  Xinyi Liu,et al.  Rufy3, a protein specifically expressed in neurons, interacts with actin‐bundling protein Fascin to control the growth of axons , 2014, Journal of neurochemistry.

[46]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[47]  Dushyant Kumar,et al.  The Correlation of Hippocampal T2-Mapping with Neuropsychology Test in Patients with Alzheimer’s Disease , 2013, PloS one.

[48]  Christian Langkammer,et al.  MRI for Iron Mapping in Alzheimer's Disease , 2013, Neurodegenerative Diseases.

[49]  Torsten Rohlfing,et al.  MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping , 2011, NeuroImage.

[50]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[51]  Hua-wei Ling,et al.  Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease , 2009, Journal of magnetic resonance imaging : JMRI.

[52]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[53]  Mark A. Smith,et al.  Induction of NADPH cytochrome P450 reductase by the Alzheimer β‐protein. Amyloid as a ‘foreign body’ , 2001, Journal of neurochemistry.

[54]  J. Rogers,et al.  Perturbed iron distribution in Alzheimer's disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. , 2014, Journal of Alzheimer's disease : JAD.

[55]  B. Møller,et al.  Conformational changes of the NADPH-dependent cytochrome P450 reductase in the course of electron transfer to cytochromes P450. , 2011, Biochimica et biophysica acta.